Autologous hematopoietic stem cell transplantation is considered the standard of care for younger patients with multiple myeloma. Several mobilization regimens are currently used, most commonly growth factors alone or in combination with chemotherapy. The aim of our study was to investigate the differences in lymphocyte subpopulation counts between three different mobilization regimens on collection day, in the leukapheresis product and on day 15 after autologous hematopoietic stem cell transplantation
Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells...
Autologous stem cell transplantation (ASCT) is considered the standard therapy for younger patients ...
The optimal stem cell (SC) mobilization strategy for patients with multiple myeloma (MM) remains a m...
Background The lymphocyte dose (LY-DO) infused during an autograft influences absolute lymphocyte (A...
Autologous stem cell transplantation (ASCT), supported by high-dose chemotherapy, is the prevalent o...
In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (aut...
In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (aut...
Autologous stem cell transplantation is an important part of therapy in patients with multiple myelo...
Background: Multiple myeloma is currently the leading indication for autologous hematopoietic cell t...
Abstract Background For successful autologous stem cell transplantation, the collection of a suffici...
As more efficient agents for stem cell mobilization are being developed, there is an urgent need to ...
Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide (ID-CY) and gr...
Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with m...
Cyclophosphamide along with recombinant human granulocyte-colony stimulating factor (rhG-CSF) is a c...
This study presents a new method of combined growth factor mobilization with increased dose (15 μg/k...
Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells...
Autologous stem cell transplantation (ASCT) is considered the standard therapy for younger patients ...
The optimal stem cell (SC) mobilization strategy for patients with multiple myeloma (MM) remains a m...
Background The lymphocyte dose (LY-DO) infused during an autograft influences absolute lymphocyte (A...
Autologous stem cell transplantation (ASCT), supported by high-dose chemotherapy, is the prevalent o...
In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (aut...
In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (aut...
Autologous stem cell transplantation is an important part of therapy in patients with multiple myelo...
Background: Multiple myeloma is currently the leading indication for autologous hematopoietic cell t...
Abstract Background For successful autologous stem cell transplantation, the collection of a suffici...
As more efficient agents for stem cell mobilization are being developed, there is an urgent need to ...
Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide (ID-CY) and gr...
Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with m...
Cyclophosphamide along with recombinant human granulocyte-colony stimulating factor (rhG-CSF) is a c...
This study presents a new method of combined growth factor mobilization with increased dose (15 μg/k...
Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells...
Autologous stem cell transplantation (ASCT) is considered the standard therapy for younger patients ...
The optimal stem cell (SC) mobilization strategy for patients with multiple myeloma (MM) remains a m...